Combining GLP-1 receptor agonists and SGLT-2 inhibitors for cardiovascular disease prevention in type 2 diabetes: A systematic review with multiple network meta-regressions.
結合 GLP-1 受體激動劑和 SGLT-2 抑制劑以預防 2 型糖尿病的心血管疾病:一項包含多重網絡元回歸的系統性回顧。
World J Diabetes 2024-11-04
GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Patients With Versus Without Cardiovascular Disease: A Systematic Review, Meta-analysis, and Trial Sequential Analysis.
GLP-1受體激動劑和SGLT-2抑製劑在具有心血管疾病與無心血管疾病患者中的應用:系統性回顧、荟萃分析和試驗序列分析。
Angiology 2023-06-16
GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes.
GLP-1 受體激動劑治療在第2型糖尿病患者中的應用:單獨使用及與 SGLT2 抑制劑合併治療。
J Am Coll Cardiol 2023-08-04
Effectiveness and safety of the combination of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies.
二型糖尿病患者合併使用鈉葡萄糖轉運蛋白2抑制劑和葡萄糖樣肽-1受體激動劑的效果和安全性:觀察性研究的系統性回顧和荟萃分析。
Cardiovasc Diabetol 2024-03-21
Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database.
結合 pioglitazone 與鈉葡萄糖共同運輸蛋白-2 抑制劑或葡萄糖樣肽-1 受體激動劑對第2型糖尿病結果的影響:來自國際聯合數據庫的系統性回顧、荟萃分析和實際研究。
Diabetes Obes Metab 2024-04-01
Efficacy and Safety of the Combination or Monotherapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: An update Systematic Review and Meta-analysis.
GLP-1受體激動劑和SGLT-2抑制劑在2型糖尿病中的聯合或單獨治療的功效和安全性:最新系統性回顧和荟萃分析。
Am J Med Sci 2024-07-08
Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
GLP-1 受體激動劑單獨及與 SGLT2 抑制劑聯合使用在 2 型糖尿病中的心血管、腎臟及安全性結果:系統性回顧與統合分析。
Circulation 2024-08-30
GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy.
GLP-1 受體激動劑與 SGLT2 抑制劑在 2 型糖尿病中的作用:多重心代謝效應及聯合療法的附加價值。
Drugs 2024-09-28
Effects of glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in high-risk type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
高風險第二型糖尿病患者中,胰高血糖素樣肽-1受體激動劑對心血管結果的影響:隨機對照試驗的系統評價與荟萃分析。
Diabetol Metab Syndr 2024-10-25
One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA.
一個還是兩個?SGLT2i或GLP1RA的聯合療法與單一療法之間心腎效應的比較。
Diabetes Obes Metab 2024-11-21